[
  {
    "ts": null,
    "headline": "Merck Indicates Better Growth Visibility in Post-Keytruda LOE Period",
    "summary": "MRK outlines solid long-term outlook with more than $70B opportunity beyond Keytruda LOE, backed by pipeline progress, new product launches and M&A deals.",
    "url": "https://finnhub.io/api/news?id=92ad35f6f3d24f7c3a41d26bcbaf8bced9e726be13146d2a3d17925cce202876",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771260300,
      "headline": "Merck Indicates Better Growth Visibility in Post-Keytruda LOE Period",
      "id": 139116648,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "MRK outlines solid long-term outlook with more than $70B opportunity beyond Keytruda LOE, backed by pipeline progress, new product launches and M&A deals.",
      "url": "https://finnhub.io/api/news?id=92ad35f6f3d24f7c3a41d26bcbaf8bced9e726be13146d2a3d17925cce202876"
    }
  },
  {
    "ts": null,
    "headline": "Prothena Stock Tumbles 36.8% Year Over Year: What Lies Ahead?",
    "summary": "PRTA stock declines 36.8% in a year as birtamimab's failure, earnings miss and reliance on partner programs weigh on investor confidence.",
    "url": "https://finnhub.io/api/news?id=fd05ff580f6a7d8859b891fb0f757a7a91e5f2fffe13aa97d26623ebfaecc5d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771253640,
      "headline": "Prothena Stock Tumbles 36.8% Year Over Year: What Lies Ahead?",
      "id": 139115837,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRTA stock declines 36.8% in a year as birtamimab's failure, earnings miss and reliance on partner programs weigh on investor confidence.",
      "url": "https://finnhub.io/api/news?id=fd05ff580f6a7d8859b891fb0f757a7a91e5f2fffe13aa97d26623ebfaecc5d8"
    }
  },
  {
    "ts": null,
    "headline": "Theranostics earmarked as “the future” of radiopharmaceuticals",
    "summary": "As RLTs and theranostics gain prevalence, companies must consider how to overcome their associated regulatory, manufacturing and reimbursement hurdles.",
    "url": "https://finnhub.io/api/news?id=42dc355fe9c2aba8a6bdb17b008a2dc221790295e37a66d7cf9aaec99105950b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771236000,
      "headline": "Theranostics earmarked as “the future” of radiopharmaceuticals",
      "id": 139116629,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "As RLTs and theranostics gain prevalence, companies must consider how to overcome their associated regulatory, manufacturing and reimbursement hurdles.",
      "url": "https://finnhub.io/api/news?id=42dc355fe9c2aba8a6bdb17b008a2dc221790295e37a66d7cf9aaec99105950b"
    }
  }
]